If the cells you would like to access are currently listed as unavailable
or you are ordering from outside of Europe please get in touch via
Contact@EBiSC.org.
CIRAi005-A-1
IsC2-F2KU1#4, IsC-F2KU1
Gene-edited iPSC line
The cell line is not released.
General#
Cell Line |
|
| hPSCreg name | CIRAi005-A-1 |
| Alternative name(s) |
IsC2-F2KU1#4, IsC-F2KU1
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Notes | FSHD2 patient-derived iPSC with SMCHD1 mutation corrected and without transgenes |
Provider |
|
| Depositor | Center for iPS Cell Research and Application (CIRA) |
| Owner | Center for iPS Cell Research and Application (CIRA) |
| Distributors |
Center for iPS Cell Research and Application (CIRA)
|
| Derivation country | Japan |
External Databases |
|
| hPSCreg | CIRAi005-A-1 |
| BioSamples | SAMEA7001537 |
| Cellosaurus | CVCL_ZA42 |
| Wikidata | Q98125627 |
General Information |
|
| This EBiSC line can be used for: |
Yes
Research use: allowed
Clinical use: no
Commercial use: no
|
| Subclone of | (not in EBiSC, see CIRAi005-A in hPSCreg) |
Donor Information#
General Donor Information |
|
| Sex | female |
| Ethnicity | Japanese |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor |
|
External Databases (Donor) |
|
| BioSamples | SAMEA6983573 |
hIPSC Derivation#
General |
|
|
More source cell information can be found in the parental cell line
CIRAi005-A in hPSCreg.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Laminin |
| Feeder cells |
No |
| Passage method |
Enzymatically
Accutase
|
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: StemFit® AK02N
Main protein source: Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| NANOG |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
||||
| SOX2 |
Yes |
|
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| FOXA2 |
Yes |
| SOX17 |
Yes |
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Genetic Modification#
| Disease/phenotype related modifications |
|